Nanobac Pharmaceuticals Releases New Portrait of Calcifying Nanoparticles, Related Announcement to Follow
Thursday October 26, 9:50 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Scientists for Nanobac Pharmaceuticals Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") have published a new outlook on the role of calcifying nanoparticles (CNPs) in diseases such as atherosclerosis and kidney stones, setting the groundwork for what company officials call a "significant" announcement next week.
Entitled "What are Calcifying Nanoparticles?" the document on the company's Web site provides, for the first time, investors and journalists with a clear picture of the state of science on CNPs, formerly known as nanobacteria, and summarizes the role CNPs play in one of the most pervasive medical conditions in existence: calcification of arteries and organs.
"We decided to publish this summary so journalists and investors could have a clear idea of what the particles are before we release research next week that will show surprising new results," explained Nanobac Co-Chair Dr. Benedict Maniscalco.
The summary was completed following a conference earlier this month at the University of Auburn, sponsored by the Fetzer Memorial Trust, a non-profit foundation dedicated to bringing leading edge technologies to the forefront.
"After a lot of probing questions from some of the leading scientists in their field, our organization was able to assemble a document that accurately describes the state of knowledge on what CNPs are, what they do to us, and why interest in this pathogen is growing," Dr. Maniscalco added.
For years scientists have been struggling to assemble a snapshot of the "state of knowledge" about CNPs. The document was assembled to fill that gap.
One of the issues raised about CNPs is whether they are any different from calcified crystals that are found in kidney stones and hardening of the arteries.
"Our announcement (including video evidence) next week will show there is a difference, and that difference will explain a lot about why present therapies against calcification have been ineffective," Maniscalco said.
"In preparation for that announcement, and because there have been debates over what the particles actually are, we decided to gather the state of knowledge to date for everybody to see and discuss," he concluded.
Final work is still being done on video microscopy evidence assembled by Nanobac scientists, in preparation for its release next week. The new summary document "What Are Calcifying Nanoparticles (CNPs)?" is available at nanobac.com .
About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals, Tampa
Douglas Mulhall, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348
Source: Nanobac Pharmaceuticals Inc. |
